STAT+: Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a lauded cancer researcher’s lab.
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of lauded cancer researcher Bert Vogelstein’s lab.
The Boston-based company, Cage Pharma, has already received funding from Catalio Capital Management and hopes to raise up to $35 million in a Series A round, according to a person with knowledge of the company’s plans. Catalio co-founder and managing partner R. Jacob Vogelstein confirmed the plans, adding that the financing round should fuel the company for long enough to yield clinical data.
Catalio has been working closely with Bert Vogelstein’s lab at Johns Hopkins University over the last several years to turn a therapy that is toxic on its own into a viable treatment for several different types of cancer. (Bert Vogelstein is a venture partner at Catalio and father to co-founder Jacob Vogelstein. Catalio has invested in multiple companies based on Bert Vogelstein’s research, including Thrive Earlier Detection and Haystack Oncology, both of which were quickly acquired.)
